Methotrexate still works: comment on the articles by Rohr et al and Hirata et al

Every time we discuss rheumatoid arthritis (RA), we talk about early diagnosis, treat-to-target therapy, cost-effectiveness between biological and non-biological therapies, the role of disease activity meters, and when and how a biological therapy should be discontinued. Amidst this whirlwind of information, where yesterday's evidence is not the same as today, methotrexate (MTX) remains the cornerstone therapy for patients with RA. This article is protected by copyright. All rights reserved.